Literature DB >> 422308

Pharmacokinetics of carbamazepine in the neonate and in the child.

E Rey, P d'Athis, D de Lauture, O Dulac, J Aicardi, G Olive.   

Abstract

1. Pharmacokinetic of carbamazepine were made in 7 new-borns and in 5 children. They were hospitalized for epilepsy and were receiving drugs such as phenobarbital alone or in association with other antiepileptic drugs, but not with carbamazepine. 2. The drug was given by oral route with a mean dose of 17.2 mg.kg-1. 3. The determination of carbamazepine concentration in serum was made by gas liquid chromatography on a 50 microliter sample. 4. A one compartment body model was used to determine the pharmacokinetic constants with first order rate constants for absorption and elimination. 5. Absorption was generally delayed by about half an hour, the maximum concentrations ranging from 3.14 to 10 microgram.ml-1 at 2 and 9 hr after administration. The mean half-life for absorption was 1.42 +/- 0.34 hr. The mean half-life for elimination was 8.76 +/- 0.85 hr. The half-life for elimination was much shorter than those already described even in multiple dosing epileptic adult patients. The pharmacokinetic parameters were used to predict blood levels in chronic treatment in 3 children. The predicted steady state concentrations disagreed with the concentrations measured.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 422308

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  12 in total

Review 1.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

Review 2.  Clinical pharmacology of the perinatal period and early infancy.

Authors:  P L Morselli
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 3.  Diagnosis and treatment of epilepsy in children and adolescents.

Authors:  L D Morton; J M Pellock
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 4.  Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics.

Authors:  H Nau; W Kuhnz; H J Egger; D Rating; H Helge
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

5.  Anticonvulsants in the newborn period.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1985 Sep-Oct       Impact factor: 1.967

6.  Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication.

Authors:  B Summers; R S Summers
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Saliva carbamazepine levels in children before and during multiple dosing.

Authors:  T A Moreland; D A Priestman; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

10.  A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures.

Authors:  Joanie K Tulloch; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.